| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ribrag V et al. | A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. | 2014 | Clin. Cancer Res. | pmid:24132920 |
| Krop I and Winer EP | Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. | 2014 | Clin. Cancer Res. | pmid:24135146 |
| Krop IE et al. | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. | 2014 | Lancet Oncol. | pmid:24793816 |
| Gnant M et al. | HER2-positive breast cancer: a new piece of the puzzle. | 2014 | Lancet Oncol. | pmid:24793817 |
| Wright J | Nanotechnology: Deliver on a promise. | 2014 | Nature | pmid:24870822 |
| Montemurro F | HER2 expression and efficacy of T-DM1. | 2014 | Breast Cancer Res. | pmid:25472666 |
| Vigne E and Sassoon I | [The growing field of immunoconjugates in oncology. A successful link(er) between antibodies and small cytotoxic molecules]. | 2014 | Med Sci (Paris) | pmid:25311020 |
| Feng L et al. | Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. | 2014 | Clin. Cancer Res. | pmid:25294907 |
| Field JJ et al. | A previously undescribed tubulin binder. | 2014 | Proc. Natl. Acad. Sci. U.S.A. | pmid:25187564 |
| Torres S et al. | Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. | 2014 | BMJ Case Rep | pmid:25123575 |
| Kim M et al. | Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer. | 2014 | Curr. Opin. Obstet. Gynecol. | pmid:24335887 |
| Miller KD et al. | Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. | 2014 | J. Clin. Oncol. | pmid:24733796 |
| Lu D et al. | Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. | 2014 | Cancer Chemother. Pharmacol. | pmid:24939213 |
| Villanueva MT | Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer. | 2014 | Nat Rev Clin Oncol | pmid:24913372 |
| Bhardwaj AS et al. | A case of vasculitis in a breast cancer patient treated with T-DM1. | 2014 | Semin. Oncol. | pmid:25440614 |
| Mancuso L et al. | Preparation of thermocleavable conjugates based on ansamitocin and superparamagnetic nanostructured particles by a chemobiosynthetic approach. | 2014 | Chemistry | pmid:25346489 |
| Teplinsky E and Muggia F | Targeting HER2 in ovarian and uterine cancers: challenges and future directions. | 2014 | Gynecol. Oncol. | pmid:25220628 |
| Pillow TH et al. | Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. | 2014 | J. Med. Chem. | pmid:25191794 |
| Wada R et al. | Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. | 2014 | Cancer Chemother. Pharmacol. | pmid:25186956 |
| Hussar DA | New drugs 2014, part 3. | 2014 | Nursing | pmid:25153167 |